The leading provider of Next Generation Sequencing analysis solutions, CLC bio, has started a new expansion phase of the distribution of its Next Generation Sequencing solutions into the Japanese market.

To handle direct relations with its Japanese customers, CLC bio has accepted Filgen Inc as its new reseller. Additionally, to oversee its Japan operations, CLC bio has appointed David Leangen as CEO of CLC bio Japan. Leangen is a Canadian expat and long-time Japan resident with great experience in the Japanese life science sector.

Director of Partner Sales at CLC bio, Michael Heltzen, said, "In 2009 we have experienced a considerable increase of interest in our solutions from Japan. This is logically linked with the significant increase of Next Generation Sequencing instruments being installed, which in turn requires analysis capacity of the huge amounts of data - an area where we excel. We regard the Japanese life science sector as one of the premier markets in Asia and are happy to announce this setup, so we can support our current and upcoming customers in Japan in the best possible way!"

Manabu Harada of Filgen continued, "We are pleased to have the opportunity of becoming a sales partner with CLC bio. Since we work in this field on a daily basis, we have a chance to sense the needs of our customers. Next Generation Sequencing is becoming a big thing in Japan, and the products offered by CLC bio fill an important need."

Newly appointed CEO of CLC bio Japan, David Leangen, adds, "I have been very impressed by CLC bio. Not only are they able to adapt quickly to a newly emerging market, but they have shown that they have what it takes to adapt to the very difficult conditions of the Japanese market as well. Filgen has shown that they are a dynamic company, so I see great synergy in this relationship. With the help of Filgen, I am confident that we will be able to grab an important share of the Japanese market over the coming years."